Healthcare 2013, 1(1), 96-99; doi:10.3390/healthcare1010096
Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser
Department of Dermatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
*
Author to whom correspondence should be addressed.
Received: 20 August 2013 / Revised: 16 October 2013 / Accepted: 21 October 2013 / Published: 25 October 2013
Abstract
No particular regimen is considered standard therapy for widespread metastatic melanoma, although surgery is the primary choice for regional nodal metastases. Systemic interleukin-2 (IL-2) is an effective immunotherapy for melanoma, but standard doses are associated with severe toxicity. We report a patient who was treated with intralesional low-dose IL-2 and V-beam pulsed dye laser for the treatment of scalp melanoma metastases. This treatment resulted in rapid regression of metastatic tumors with limited adverse effects. View Full-TextKeywords:
interleukin-2; melanoma; pulsed dye laser therapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Scifeed alert for new publications
Never miss any articles matching your research from any publisher- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Share & Cite This Article
MDPI and ACS Style
Wang, M.Z.; Brewer, J.D. Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser. Healthcare 2013, 1, 96-99.
Related Articles
Article Metrics
Comments
[Return to top]
Healthcare
EISSN 2227-9032
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert